dCK Antibody (2243C2): sc-81245
- dCK Antibody (2243C2) is a mouse monoclonal IgG1, cited in 5 publications, provided at 100 µg/ml
- raised against a recombinant protein corresponding to a region near the N-terminus of dCK of human origin
- recommended for detection of dCK of human origin by WB and IP
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for dCK Antibody (2243C2). This work is in progress.
QUICK LINKS
SEE ALSO...
dCK Antibody (2243C2) is a mouse monoclonal IgG1 antibody that detects deoxycytidine kinase (dCK) in human samples through western blotting (WB) and immunoprecipitation (IP) applications. dCK plays a crucial role in the metabolism of nucleosides, catalyzing the phosphorylation of deoxycytidine to deoxycytidine monophosphate, which is essential for DNA synthesis and repair. This enzymatic activity is particularly important in cancer therapy, as anti-dCK antibody (2243C2) targets a protein involved in activating several nucleoside analogs used in chemotherapy. dCK deficiency is linked to resistance against antiviral and chemotherapeutic agents, highlighting dCK′s significance in drug response and resistance mechanisms. dCK protein is predominantly localized in the cytosol, where dCK interacts with various nucleoside triphosphates to facilitate phosphorylation activity. Understanding dCK function and regulation is vital for developing strategies to overcome drug resistance in cancer and viral infections, making dCK monoclonal antibody (2243C2) an invaluable tool for researchers studying these critical pathways.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
dCK Antibody (2243C2) References:
- Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance. | Bunimovich, YL., et al. 2014. PLoS One. 9: e104125. PMID: 25101980
- Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer. | Kerr, M., et al. 2014. Clin Cancer Res. 20: 5435-45. PMID: 25224279
- Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy. | Lachmann, N., et al. 2015. Leukemia. 29: 2266-9. PMID: 25921248
- Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia. | Degwert, N., et al. 2016. Eur J Haematol. 97: 239-44. PMID: 26613208
- Deoxycytidine kinase participates in the regulation of radiation-induced autophagy and apoptosis in breast cancer cells. | Zhong, R., et al. 2018. Int J Oncol. 52: 1000-1010. PMID: 29393406
- Engineered Thymidine-Active Deoxycytidine Kinase for Bystander Killing of Malignant Cells. | Neschadim, A. and Medin, JA. 2019. Methods Mol Biol. 1895: 149-163. PMID: 30539536
- Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine. | Wu, B., et al. 2021. Acta Haematol. 144: 534-541. PMID: 33626530
- Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency. | Guantay, L., et al. 2023. Drug Resist Updat. 67: 100932. PMID: 36706533
- Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. | Dash, S., et al. 2024. Cell Death Dis. 15: 131. PMID: 38346958
- Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. | Ruiz van Haperen, VW., et al. 1993. Eur J Cancer. 29A: 2132-7. PMID: 8297652
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
dCK Antibody (2243C2) | sc-81245 | 100 µg/ml | $333.00 |